CA2976383C - Iloperidone for the treatment of schizophrenia - Google Patents

Iloperidone for the treatment of schizophrenia Download PDF

Info

Publication number
CA2976383C
CA2976383C CA2976383A CA2976383A CA2976383C CA 2976383 C CA2976383 C CA 2976383C CA 2976383 A CA2976383 A CA 2976383A CA 2976383 A CA2976383 A CA 2976383A CA 2976383 C CA2976383 C CA 2976383C
Authority
CA
Canada
Prior art keywords
iloperidone
daily dose
acceptable salt
patients
maintenance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2976383A
Other languages
English (en)
French (fr)
Other versions
CA2976383A1 (en
Inventor
Mihael H. Polymeropoulos
Curt D. Wolfgang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of CA2976383A1 publication Critical patent/CA2976383A1/en
Application granted granted Critical
Publication of CA2976383C publication Critical patent/CA2976383C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2976383A 2015-02-17 2016-02-17 Iloperidone for the treatment of schizophrenia Active CA2976383C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562117173P 2015-02-17 2015-02-17
US62/117,173 2015-02-17
US201562172436P 2015-06-08 2015-06-08
US62/172,436 2015-06-08
PCT/US2016/018316 WO2016134049A1 (en) 2015-02-17 2016-02-17 Iloperidone for the treatment of schizophrenia

Publications (2)

Publication Number Publication Date
CA2976383A1 CA2976383A1 (en) 2016-08-25
CA2976383C true CA2976383C (en) 2023-05-23

Family

ID=55532275

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2976383A Active CA2976383C (en) 2015-02-17 2016-02-17 Iloperidone for the treatment of schizophrenia

Country Status (9)

Country Link
US (2) US10441580B2 (enExample)
EP (1) EP3258935B1 (enExample)
JP (1) JP6885649B2 (enExample)
KR (1) KR102870956B1 (enExample)
CN (2) CN116211857A (enExample)
BR (1) BR112017017608A2 (enExample)
CA (1) CA2976383C (enExample)
ES (1) ES2870498T3 (enExample)
WO (1) WO2016134049A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214827B2 (en) * 2018-08-30 2022-01-04 Vanda Pharmaceuticals Inc. Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone
JP2026504721A (ja) * 2022-12-19 2026-02-09 バンダ・ファーマシューティカルズ・インコーポレイテッド 双極ｉ型障害及び統合失調症の治療のためのイロペリドンの投与レジメン
WO2024249952A1 (en) 2023-06-02 2024-12-05 Vanda Pharmaceuticals Inc. Method of treatment with iloperidone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2305656T3 (da) 2001-08-31 2013-02-11 Novartis Ag Optiske isomerer of en iloperidonmetabolit
ES2358416T3 (es) 2001-10-30 2011-05-10 Novartis Ag Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20100063093A1 (en) * 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA3113166A1 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
WO2009036056A1 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
KR20100099292A (ko) * 2007-12-19 2010-09-10 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
CA2760474C (en) * 2009-05-15 2020-08-18 Vanda Pharmaceuticals Inc. Antipsychotic treatment based on drd2 or ankk1 snp genotype
EP2785347A1 (en) * 2011-12-02 2014-10-08 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
IN2014DN08495A (enExample) 2012-03-14 2015-05-08 Vanda Pharmaceuticals Inc
IL275725B (en) * 2012-08-21 2022-08-01 Sage Therapeutics Inc Treatment methods for epilepsy and status epilepticus

Also Published As

Publication number Publication date
HK1248551A1 (zh) 2018-10-19
BR112017017608A2 (en) 2018-05-08
US20180021324A1 (en) 2018-01-25
JP2018505901A (ja) 2018-03-01
CN116211857A (zh) 2023-06-06
ES2870498T3 (es) 2021-10-27
EP3258935A1 (en) 2017-12-27
CN107249586A (zh) 2017-10-13
US10441580B2 (en) 2019-10-15
EP3258935B1 (en) 2021-04-07
JP6885649B2 (ja) 2021-06-16
WO2016134049A1 (en) 2016-08-25
CA2976383A1 (en) 2016-08-25
KR102870956B1 (ko) 2025-10-16
US20190388412A1 (en) 2019-12-26
KR20170118830A (ko) 2017-10-25
US10987346B2 (en) 2021-04-27

Similar Documents

Publication Publication Date Title
Bowden et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
Zajecka et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder
Hermann et al. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
US10987346B2 (en) Iloperidone for the treatment of schizophrenia
Shiovitz et al. A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120mg/day for prevention of relapse in patients with major depressive disorder
JP2024050575A (ja) Ｌ－４－クロロキヌレニンの治療的使用
Rui et al. Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia
Allgulander et al. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder
KR20240060820A (ko) 혈전색전성 장애의 예방 및 치료를 위한 밀벡시안
JP2017128610A (ja) 併用ａｌｓ療法
JP2015522077A5 (enExample)
Bennett et al. The role of ondansetron in the treatment of schizophrenia
KR102642795B1 (ko) 망막 질환을 치료하기 위한 미라베그론
HK1248551B (en) Iloperidone for the treatment of schizophrenia
Doyle et al. Psychotropic medications, associated QTc prolongation, and sudden cardiac death: a review for clinicians
CN106999449A (zh) 用于治疗多汗症的方法
Qiu et al. Metformin alleviates ribociclib-induced lung injury by restoring impaired autophagy via targeting Mucolipin-1
Xin et al. Zhengzhou University, Zhengzhou, China
Placebo-Controlled Long-Term Remission With Cariprazine Treatment in Patients With Schizophrenia
Takekita et al. P. 3. c. 024 Comparison of perospirone and aripiprazole: a 12 weeks, randomised, open-label study in Japanese schizophrenia patients
JP2018507216A (ja) 多発性骨髄腫に対するパノビノスタット投与量
Ding et al. Does Perioperative Use of Renin-Angiotensin System Inhibitors Improve Patient Outcomes in Cardiac Surgery?
WO2021255438A1 (en) Combination of dexamethasone and a mineralocorticoid receptor antagonist for use in the treatment of acute respiratory distress syndrome
Rajiv et al. First-line Therapy in Status Epilepticus
CN108938645A (zh) 一种抗精神病药物组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201016

EEER Examination request

Effective date: 20201016

EEER Examination request

Effective date: 20201016

EEER Examination request

Effective date: 20201016

EEER Examination request

Effective date: 20201016

EEER Examination request

Effective date: 20201016

EEER Examination request

Effective date: 20201016

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207